

BC Cancer Protocol Summary for DOXOrubicin for Use in Patients with Advanced Uterine Sarcoma

Protocol Code	GOSAD
Tumour Group	Gynecologic Oncology
Contact Physician	Dr. Anna Tinker

ELIGIBILITY:

- Patients with an advanced uterine sarcoma
- Good performance status

EXCLUSIONS:

- Poor bone marrow reserve, renal dysfunction, hepatic dysfunction (bilirubin greater than 2xULN)

TESTS:

- Baseline: CBC & diff, platelets, creatinine, bilirubin, ALT, alk phos and clinical measure of tumour response. *If clinically indicated: GGT*
- **Before each treatment:** CBC & diff, platelets, ALT, alk phos, bilirubin, clinical measure of tumour response. *If clinically indicated: creatinine*
- Every second treatment: appropriate imaging to monitor response

PREMEDICATIONS:

- Antiemetic protocol for High/Moderate emetogenic chemotherapy (see protocol SCNAUSEA)

TREATMENT:

Drug	Dose	BC Cancer Administration Guidelines
DOXOrubicin	75 mg/m ²	IV push

- For patients greater than 65 years old, consider reducing dose to 60 mg/m²
- Repeat every 21 days x 6 cycles

DOSE MODIFICATIONS:

1. Hematological:

ANC (x 10 ⁹ /L)		Platelets (x 10 ⁹ /L)	Dose
greater than 1.5	and	greater than 100	100 %
1 to 1.5	or	70 to 100	80 %
less than 1	or	less than 70	Delay one week

- Mucositis:** Grade 3 or 4, reduce dose to 80%
- Nausea & Vomiting:** Grade 4 despite optimal use of antiemetics, reduce dose to 80% or QUIT
- Neutropenic Fever** (with ANC less than 0.5 x 10⁹/L): Once counts have recovered, reduce dose to 80%
- Hepatic Dysfunction:** For bilirubin 1.5 to 2 times ULN, reduce dose to 50%

PRECAUTIONS:

- Cardiac Toxicity:** DOXOrubicin is cardiotoxic and must be used with caution in patients with severe hypertension or cardiac dysfunction. Cardiac assessment is recommended if lifelong dose of 450 mg/m² is exceeded (see [BC Cancer Drug Manual](#)).
- Extravasation:** DOXOrubicin causes pain and tissue necrosis if extravasated. Refer to [BC Cancer Extravasation Guidelines](#).
- Neutropenia:** Fever or other evidence of infection must be assessed promptly and treated aggressively.

Call Dr. Anna Tinker or tumour group delegate at (604) 877-6000 or 1-800-663-3333 with any problems or questions regarding this treatment program.